Author’s response to reviews

Title: Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (Flr-B/FOx) according to extension of metastatic disease

Authors:

Gemma Bruera (gemma.gbb@gmail.com)
Katia Cannita (kcannita@gmail.com)
Daniela Di Giacomo (daniela.digiacomo@alice.it)
Aude Lamy (aude.lamy@chu-rouen.fr)
Giancarlo Troncone (giancarlo.troncone@unina.it)
Antonella Dal Mas (antonelladalmas@yahoo.it)
Gino Coletti (screening.aquila@gmail.com)
Thierry Frebourg (thierry.frebourg@chu-rouen.fr)
Jean Christophe Sabourin (jean-christophe.sabourin@chu-rouen.fr)
Mario Tosi (Mario.Tosi@univ-rouen.fr)
Corrado Ficorella (corrado.ficorella@univaq.it)
Enrico Ricevuto (enrico.ricevuto@univaq.it)

Version: 4 Date: 20 September 2012

Author’s response to reviews: see over
Enclosed you’ll find the manuscript 1158812950717649 “Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOX) according to extension of metastatic disease”, by Gemma Bruera et al., revised in light of the reviewer’s comments.

A point-by-point response to the comments is described in this cover letter and has been provided in the revised manuscript, submitted in a marked up version that highlights the changes that we have made in a different colour.

Referee 2:

“My only consideration at present, regards the non-significant statistical differences in OS, PFS and OS in patients O/MM. I believe that it could be dependent by the relatively low number of cases. I think that this point deserves a small comment in the text.”

We integrated the comment concerning prognosis of liver-limited compared to other/multiple metastatic disease in KRAS mutant MCRC patients in Discussion, page 16: “In KRAS mutant pts, prevalently harbouring c.35 G > A transversion (53.5%), integrated medical and surgical treatment failed to significantly increase PFS and OS in L-L compared to O/MM pts: median PFS was equivalent (11 months), in spite of 54% performed liver metastasectomies in L-L pts; median OS
was trendly different (39 and 19 months, respectively), even if it should be evaluated in a larger cohort of MCRC patients”.

We thank very much for the contribution to further increase the relevance of our article for publication in BMC Medicine.

Sincerely,

Enrico Ricevuto

Enrico Ricevuto, M.D.
U.O.C. Medical Oncology,
S. Salvatore Hospital,
University of L’Aquila,
Via Vetoio, Coppito (L'Aquila), 67100, Italy
Tel/Fax +390862368682
e-mail enrico.ricevuto@univaq.it